Estrella Immunopharma, Inc.
ESLA
$1.72
$0.148.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | 2.36M | 2.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 8.82M | 8.82M |
| Operating Income | -- | -- | -- | -8.82M | -8.82M |
| Income Before Tax | -- | -- | -- | -8.82M | -8.82M |
| Income Tax Expenses | -- | -- | -- | 1.60K | 1.60K |
| Earnings from Continuing Operations | -- | -- | -- | -8.82 | -8.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -8.82M | -8.82M |
| EBIT | -- | -- | -- | -8.82M | -8.82M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | -- | -0.24 | -0.24 |
| Normalized Basic EPS | -- | -- | -- | -0.15 | -0.15 |
| EPS Diluted | -- | -- | -- | -0.24 | -0.24 |
| Normalized Diluted EPS | -- | -- | -- | -0.15 | -0.15 |
| Average Basic Shares Outstanding | -- | -- | -- | 143.31M | 143.31M |
| Average Diluted Shares Outstanding | -- | -- | -- | 143.31M | 143.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |